ライフサイエンスコーパス: Avastin

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 the novel anti-angiogenic agent bevacizumab (Avastin).

2 of GLV-1h68 and multiple i.p. injections of Avastin.

3 The recent approval of bevacizumab (Avastin), a humanized anti-vascular endothelial growth f

4 Drug Administration approval of bevacizumab (Avastin), a recombinant humanized anti-vascular endothel

5 Currently, one clinical trial is studying Avastin alone for acute vision-threatening ROP stage 3 i

6 Recent reports detail the use of Avastin alone, and in combination with light amplificati

7 he introduction and approval of bevacizumab (Avastin), an anti-vascular endothelial growth factor ant

8 fic binding to other therapeutic antibodies (Avastin and Rituxan) was observed.

9 (Ozurdex), along with off-label bevacizumab (Avastin) and preservative-free triamcinolone, has signif

10 ons in the therapeutic antibody bevacizumab (Avastin) and the model anti-fluorescein antibody 4-4-20.

11 not to control antibodies such as Herceptin, Avastin, and Arzerra.

12 Bevacizumab [Avastin; anti-vascular endothelial growth factor (VEGF)

13 cuss the development and use of bevacizumab (Avastin; anti-vascular endothelial growth factor antibod

14 PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Tra

15 Avastin (bevacizumab) therapy is a promising anti-vascul

16 oral injection of the VEGF-blocking antibody Avastin (bevacizumab), pharmacologic P2X7 blockade, or P

17 e possibility that VEGF antagonists, such as Avastin, could inhibit tumor growth by a mechanism invol

18 In contrast, the Avastin epitope overlaps minimally with the receptor bin

19 Another clinical trial is investigating Avastin following LASER therapy for recurrent ROP stages

20 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA) 5 mg/kg

21 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a reco

22 mmarize the relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ra

23 Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recomb

24 The Avastin in Glioblastoma trial has shown that patients ne

25 e transitions and treatment effects from the Avastin in Glioblastoma trial, costs and resource use da

26 ls in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengit

27 -stromal communication and was equivalent to Avastin in suppressing blood vessel growth in mice harbo

28 In this biosensor, Avastin is used as the specific biorecognition element,

29 element, and MGO is used as the carrier for Avastin loading.

30 sed data supports early findings, the use of Avastin may be recommended without the need for ablative

31 Avastin-mediated VEGF neutralization was capable of sign

32 Furthermore, the advantages of the Avastin-MGO-modified biosensor for VEGF detection are th

33 Bevacizumab (Avastin(R)), a monoclonal antibody against vascular endo

34 endothelial growth factor-directed antibody, Avastin, suppressed angiogenesis in mice but, as expecte

35 The ability of Avastin to prolong survival in a Phase III clinical tria

36 Avastin, which only inhibits the tumor-derived human VEG

37 Avastin will be especially useful for ROP stage 3 cases

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。